Levodopa therapy from the neuroprotection viewpoint: From a clinical outlook

Journal of Neurology

Volumn 252, Issue SUPPL. 4, 2005, Pages

  Kondo, Tomoyoshi ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Dopamine; Free radicals; Levodopa; Neuroprotection; Parkinson's disease

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; FREE RADICAL; LEVODOPA;

CLINICAL TRIAL; CONFERENCE PAPER; DEAMINATION; DOPAMINE METABOLISM; DYNAMIC EXERCISE; HUMAN; LONG TERM CARE; MOTOR DYSFUNCTION; NEUROPROTECTION; NEUROTOXICITY; NEUROTRANSMISSION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PHYSICAL ACTIVITY; PHYSIOTHERAPY; PRIORITY JOURNAL; PSYCHOSIS; TREATMENT OUTCOME;

ANIMALS; BRAIN; DOPAMINE; FREE RADICALS; HUMANS; LEVODOPA; NEURONS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE;

EID: 26644437449     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-005-4007-6     Document Type: Conference Paper

References (37)

1. Cohen G (1984) Oxy-radical toxicity in catecholamine neurons. Neurotoxicology 5(1):77-82
2. Burke WJ, Li SW, Williams EA, Nonneman R, Zahm DS (2003) 3.4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson's disease pathogenesis. Brain Res 989(2):205-213
3. Machida Y, Chiba T, Takayanagi A, Tanaka Y, Asanuma M, Ogawa N, Koyama A, Iwatsubo T, Ito S, Jansen PH, Shimizu N, Tanaka K, Mizuno Y, Hattori N (2005) Common anti-apoptotic roles of parkin and alpha-synuclein in human dopaminergic cells. Biochem Biophys Res Commun 332(1):233-240
4. Rajput AH (2001) Levodopa prolongs life expectancy and is non-toxic to substantia nigra. Parkinsonism Relat Disord 8(2):95-100
5. Parkinson Study Group (2002) Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287(13):1653-1661
6. Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, Lang AE, Rascol O, Ribeiro MJ, Remy P, Poewe WH, Hauser RA, Brooks DJ; REAL-PET Study Group (2003) Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 54(1):93-101
7. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K; Parkinson Study Group (2004) Levodopa and the progression of Parkinson's disease. N Engl J Med 351(24):2498-2508
8. Haavik J, Almas B, Flatmark T (1997) Generation of reactive oxygen species by tyrosine hydroxylase: a possible contribution to the degeneration of dopaminergic neurons? J Neurochem 68(1):328-332
9. Jenner P (2003) Oxidative stress in Parkinson's disease. Ann Neurol 53 (Suppl 3):S26-S36
10. Fahn S, Cohen G (1992) The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 32(6):804-812
11. McLaughlin BA, Nelson D, Erecinska M, Chesselet MF (1998) Toxicity of dopamine to striatal neurons in vitro and potentiation of cell death by a mitochondrial inhibitor. J Neurochem 70(6):2406-2415
12. Han SK, Mytilineou C, Cohen G (1996) L-DOPA up-regulates glutathione and protects mesencephalic cultures against oxidative stress. J Neurochem 66(2):501-510
13. Mytilineou C, Walker RH, JnoBaptiste R, Olanow CW (2003) Levodopa is toxic to dopamine neurons in an in vitro but not an in vivo model of oxidative stress. J Pharmacol Exp Ther 304(2):792-800
14. Quinn N, Parkes D, Janota I, Marsden CD (1986) Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four-year period. Mov Disord 1(1):65-68
15. Rajput AH (2001) Levodopa prolongs life expectancy and is non-toxic to substantia nigra. Parkinsonism Relat Disord 8(2):95-100
16. Ogawa N, Asanuma M, Kondo Y, Kawada Y, Yamamoto M, Mori A (1994) Differential effects of chronic L-dopa treatment on lipid peroxidation in the mouse brain with or without pretreatment with 6-hydroxydopamine. Neurosci Lett 25; 171(1-2):55-58
17. Murer MG, Dziewczapolski G, Menalled LB, Garcia MC, Agid Y, Gershanik O, Raisman-Vozari R (1998) Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol 43(5):561-575
18. Olanow CW, Watts RL, Koller WC (2001) An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 56(11 Suppl 5):S1-S88
19. Miziuno Y, Okuma Y, Kikuchi S, Kuno S, Hashimoto T, Hasegawa K, Mano Y, Miwa H, Murata M, Yamamoto M, Yokochi F, Okiyama R, Kanazawa A, Shinpo K, Chuma T, Higashi T, Maruyama T, Mizuta E, Yamazaki S; Ad Hoc Committee on the Guidelines for the Treatment of Parkinson's Disease, Japanese Neurological Society (2002) A guideline for the treatment of Parkinson's disease. Rinsho Shinkeigaku 42(5):421-494
20. Coldwell MC, Boyfield I, Brown T, Hagan JJ, Middlemiss DN (1999) Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells. Br J Pharmacol 127(7):1696-1702
21. Jenner P (2003) Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's disease. Curr Opin Neurol 16(Suppl 1):S3-S7
22. Hoehn MM (1992) The natural history of Parkinson's disease in the pre-levodopa and post-levodopa eras. Neurol Clin 10(2):331-339
23. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 342(20):1484-1491
24. Sawada H, Ibi M, Kihara T, Urushitani M, Akaike A, Kimura J, Shimohama S (1998) Dopamine D2-type agonists protect mesencephalic neurons from glutamate neurotoxicity: mechanisms of neuroprotective treatment against oxidative stress. Ann Neurol 44(1):110-119
25. Kobayashi S, Ogren SO, Hoffer BJ, Olson L (1998) Dopamine D1 and D2 receptor-mediated acute and long-lasting behavioral effects of glial cell line-derived neurotrophic factor administered into the striatum. Exp Neurol 154(2):302-314
26. Ohta K, Fujinami A, Kuno S, Sakakimoto A, Matsui H, Kawahara Y, Ohta M (2004) Cabergoline stimulates synthesis and secretion of nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor by mouse astrocytes in primary culture. Pharmacology 71(3):162-168
27. Guo H, Tang Z, Yu Y, Xu L, Jin G, Zhou J (2002) Apomorphine induces trophic factors that support fetal rat mesencephalic dopaminergic neurons in cultures. Eur J Neurosci 16(10):1861-1870
28. Bozzi Y, Vallone D, Borrelli E (2000) Neuroprotective role of dopamine against hippocampal cell death. J Neurosci 20(22):8643-8649
29. Tripanichkul W, Stanic D, Drago J, Finkelstein DI, Horne MK (2003) D2 Dopamine receptor blockade results in sprouting of DA axons in the intact animal but prevents sprouting following nigral lesions. Eur J Neurosci 17(5):1033-1045
30. Okazawa H, Murata M, Watanabe M, Kamei M, Kanazawa I (1992) Dopaminergic stimulation up-regulates the in vivo expression of brain-derived neurotrophic factor (BDNF) in the striatum. FEBS Lett 313(2):138-142
31. Lytle ME, Vander Bilt J, Pandav RS, Dodge HH, Ganguli M (2004) Exercise level and cognitive decline: the MoVIES project. Alzheimer Dis Assoc Disord 18:57-64
32. Hiwatani H, Miwa H, Kondo T, Kajimoto Y (2005) Effects of leg muscle on Parkinson's disease patients. Parkinsonism Relat Disord 11(Suppl 2):248
33. Mabandla M, Kellaway L, St Clair Gibson A, Russell VA (2004) Voluntary running provides neuroprotection in rats after 6-hydroxydopamine injection into the medial forebrain bundle. Metab Brain Dis 19:43-50
34. Smith AD, Zigmond MJ (2003) Can the brain be protected through exercise? Lessons from an animal model of parkinsonism. Exp Neurol 184:31-39
35. Tillerson JL, Caudle WM, Reveron ME, Miller GW (2003) Exercise induces behavioral recovery and attenuates neurochemical deficits in rodent models of Parkinson's disease. Neuroscience 119:899-911
36. Cohen AD, Tillerson JL, Smith AD, Schallert T, Zigmond MJ (2003) Neuroprotective effects of prior limb use in 6-hydroxydopamine-treated rats: possible role of GDNF. J Neurochem 85:299-305
37. Fisher BE, Petzinger GM, Nixon K, Hogg E, Bremmer S, Meshul CK, Jakowec MW (2005) Exercise-induced behavioral recovery and neuroplasticity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse basal ganglia. J Neurosci Res 77:378-390